BMS exclusive worldwide license agreement with PsiOxus Therapeutics for NG-348
BMS and PsiOxus Therapeutics, Ltd. announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus... Read More